

# Resource Summary Report

Generated by SPARC SAWG on Sep 16, 2026

## Luminex: 100 Flow Cytometry Analyzer System

RRID:SCR\_018025

Type: Tool

### Proper Citation

Luminex: 100 Flow Cytometry Analyzer System (RRID:SCR\_018025)

### Resource Information

**URL:** [https://pedsresearch.org/uploads/pages/img/LuminexManual\\_LX100.pdf](https://pedsresearch.org/uploads/pages/img/LuminexManual_LX100.pdf)

**Proper Citation:** Luminex: 100 Flow Cytometry Analyzer System (RRID:SCR\_018025)

**Description:** Flow cytometry analyzer system for individual labs that performs up to 100 different tests in single reaction volume and can use either magnetic beads or plain polystyrene beads.

**Synonyms:** Luminex 100 System

**Resource Type:** instrument resource

**Keywords:** ABRF, suspension array analyzer, flow cytometry, magnetic bead, polystyrene bead, analysis, Luminex Corporation, instrument, equipment

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR\\_018025.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018025.pdf)

**Resource Name:** Luminex: 100 Flow Cytometry Analyzer System

**Resource ID:** SCR\_018025

**Old URLs:** <https://www.luminexcorp.com/research-luminex-100200/>

**Record Creation Time:** 20220129T080338+0000

**Record Last Update:** 20260912T195856+0000

### Ratings and Alerts

No rating or validation information has been found for Luminex: 100 Flow Cytometry Analyzer System.

No alerts have been found for Luminex: 100 Flow Cytometry Analyzer System.

## Data and Source Information

**Source:** [SciCrunch Registry](#)

## Usage and Citation Metrics

We found 21 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [SPARC SAWG](#) .

Sirc N, et al. (2026) Functionally Characterizing the Renal Cell Carcinoma Tumor-Immune Microenvironment via Patient-Derived Ex Vivo Models. Cancer research communications, 6(2), 402.

Lee E, et al. (2026) Angiopoietin-2 aggravates Alzheimer's disease by promoting blood-brain barrier dysfunction and neuroinflammation. Cell reports, 116621.

Ye J, et al. (2026) Baseline Tumor Features and Systemic Immune Dynamics Underlying Efficacy in MSS Metastatic Colorectal Cancer Treated with Regorafenib, Ipilimumab, and Nivolumab. Cancer immunology research, 14(4), 585.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Teras LR, et al. (2026) Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts. Blood cancer journal, 16(1).

Digomann D, et al. (2025) Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. iScience, 28(11), 113871.

Bartkeviciene A, et al. (2025) Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients. Frontiers in immunology, 16, 1655258.

Rebhun RB, et al. (2025) Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. Frontiers in immunology, 16, 1672790.

Mousavi T, et al. (2025) Polyomaviruses and the risk of breast cancer: a systematic review and meta-analysis. Infectious agents and cancer, 20(1), 14.

von Itzstein MS, et al. (2025) Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(4), 639.

MacDonald WJ, et al. (2025) Inhibition of ITGB6 stimulates potent anti-tumor responses in immunocompetent mouse models of head and neck squamous cell carcinoma and pancreatic adenocarcinoma. American journal of cancer research, 15(12), 5317.

Huntington KE, et al. (2023) GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. *International journal of molecular sciences*, 24(13).

Huntington KE, et al. (2023) GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer. *bioRxiv : the preprint server for biology*.

Cognasse F, et al. (2023) Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. *EBioMedicine*, 87, 104414.

Ertveldt T, et al. (2022) Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. *Molecular cancer therapeutics*, 21(7), 1136.

Krishna BA, et al. (2022) Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID. *EBioMedicine*, 81, 104129.

Ji S, et al. (2022) Jia Wei Xiao Yao San ameliorates chronic stress-induced depression-like behaviors in mice by regulating the gut microbiome and brain metabolome in relation to purine metabolism. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 98, 153940.

Rappe JCF, et al. (2021) A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. *The Journal of experimental medicine*, 218(11).

Piccinni MP, et al. (2021) Description of the Follicular Fluid Cytokine and Hormone Profiles in Human Physiological Natural Cycles. *The Journal of clinical endocrinology and metabolism*, 106(2), e721.

Martínez-Blanco Á, et al. (2021) CD38 Deficiency Ameliorates Chronic Graft-Versus-Host Disease Murine Lupus via a B-Cell-Dependent Mechanism. *Frontiers in immunology*, 12, 713697.